Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Viviani, S., Bachanova, V., Sureda, A., McClendon, T., Lee, C., Lisano, J., Sweetenham, J.
American Society of Hematology (ASH)
Published 2018